David Johnson (left) and Maher Gandhi (right).
Two clinical trials for rare cancer treatments and a dialysis education program led by University of Queensland researchers have been awarded more than $7.6 million in grants. The funding is part of the Medical Research Future Fund 's Rare Cancers, Rare Diseases and Unmet Need Clinical Trials program. UQ Executive Dean of Medicine Professor Geoff McColl said the grants reflected the importance of research into rare diseases. "Rare diseases can be overlooked in medical research but that doesn't make the needs of patients with these conditions any less relevant or pressing," Professor McColl said. "UQ is proud to host researchers striving to fulfil unmet medical needs and those developing cutting-edge treatments on the cusp of becoming reality through clinical trials. A $3.5 million grant will fund Mater Research Institute-UQ Director of Clinical Research Professor Maher Gandhi 's clinical trial of new cell-based immunotherapies for a rare sub-type of lymphoma. "Roughly 15 to 20 per cent of diffuse large B-cell lymphoma cases are unresponsive to conventional first-line therapy," Professor Gandhi said.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
